Hyperlipidemia Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hyperlipidemia Epidemiology Forecast Report Coverage

Expert Market Research's “Hyperlipidemia Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hyperlipidemia. It projects the future incidence and prevalence rates of hyperlipidemia cases across various populations. The study covers age, gender, and type as major determinants of the hyperlipidemia population. The report highlights patterns in the prevalence of hyperlipidemia over time and projects future trends based on multiple variables.

Hyperlipidemia Understanding: Disease Overview

Hyperlipidemia is a metabolic disorder characterized by elevated levels of lipids, including cholesterol and triglycerides, in the bloodstream. It occurs due to genetic predisposition, unhealthy dietary habits, sedentary lifestyle, or underlying conditions such as diabetes mellitus and hypothyroidism. The condition is broadly classified into primary (familial or genetic) and secondary hyperlipidemia. It includes types such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia. Persistent lipid elevation contributes to atherosclerosis, increasing the risk of cardiovascular diseases such as coronary artery disease, stroke, and peripheral vascular disease.

Hyperlipidemia Epidemiology Perspective

The hyperlipidemia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hyperlipidemia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hyperlipidemia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Sonali Sharma et al., 2024, as per the ICMR-INDIAB study, hyperlipidemia-related abnormalities in India include hypercholesterolemia at 24.0%, high low-density lipoprotein cholesterol at 20.9%, low high-density lipoprotein cholesterol at 66.9%, and hypertriglyceridemia at 32.1%, indicating a substantial population burden.
• According to Quan, Zhengri, et al., 2025, about 39% of the global adult population is affected by hyperlipidemia, with prevalence rising due to aging populations, changing lifestyles, and dietary patterns, making it a significant and growing global public health concern.
• According to Yang Pan et al., 2024, hyperlipidemia prevalence was 23.3% among 489,642 participants, with younger age at diagnosis associated with higher risks of dementia, emphasizing important age-wise distribution patterns and long-term neurological health implications.
• According to Xiaofan Miao et al., 2025, gender-based differences are evident, as the association between dietary inflammatory index and hyperlipidemia prevalence was stronger in females than males, highlighting sex-specific variations and the importance of tailored prevention and management approaches.

Read more about this report - Request a Free Sample

Country-wise Hyperlipidemia Epidemiology

The hyperlipidemia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the regions, hyperlipidemia shows substantial regional variability in prevalence and risk distribution. In India, prevalence ranges widely from 10% to 73%, with higher rates in urban and obese populations, as per Dr. Roksana Parvin et al., 2022. European data indicate elevated prevalence among specific cohorts, reaching 65% in Spain and 82% in Italy in treated populations, according to Chunling Yang et al., 2022. Overall, developed regions report consistently high prevalence linked to lifestyle factors, while Asian populations exhibit distinct lipid profile patterns, highlighting regional epidemiological heterogeneity.

Hyperlipidemia: Treatment Overview

The treatment of hyperlipidemia focuses on reducing lipid levels and preventing cardiovascular complications through lifestyle modification and pharmacological therapy. Lifestyle interventions include adopting a heart-healthy diet low in saturated fats, regular physical activity, weight management, and smoking cessation. Pharmacological treatments primarily involve statins, which reduce low-density lipoprotein cholesterol levels. Other medications include fibrates, niacin, bile acid sequestrants, and cholesterol absorption inhibitors such as ezetimibe. In high-risk patients, newer therapies like proprotein convertase subtilisin/kexin type 9 inhibitors may be used to achieve optimal lipid control.

Key Questions Answered

• What are the key findings of hyperlipidemia epidemiology in the 8 major markets?
• What will be the total number of patients with hyperlipidemia across the 8 major markets during the forecast period?
• What was the country-wise hyperlipidemia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hyperlipidemia patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hyperlipidemia during the forecast period of 2026-2035?
• What are the currently available treatments for hyperlipidemia?
• What are the disease risks, signs, symptoms, and unmet needs of hyperlipidemia?

Scope of the Hyperlipidemia Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hyperlipidemia based on several factors.
• Hyperlipidemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hyperlipidemia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Familial Hypercholesterolemia Drug Pipeline Analysis Report

Familial Hypercholesterolemia Epidemiology Forecast